Kalina Andreevska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kalina Andreevska has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Valentina Petkova
Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
5 shared publications - Daniela Grekova-Kafalova
Department of Organisation and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria
4 shared publications - Milen Dimitrov
Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Medical University- Sofia, Sofia, Bulgaria
3 shared publications - Anna Todorova
Faculty of Pharmacy, Medical University Varna, 9000 Varna, Bulgaria
2 shared publications - Iana Simova
Medical University – Pleven, Pleven, Bulgaria
2 shared publications Lora Petrova
Faculty of Chemistry and Pharmacy, Sofia University “Saint Kliment Ohridski”, Sofia, Bulgaria
2 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Medical devices in Bulgaria: Regulatory framework, market dynamics, and institutional development
Bulgaria occupies a unique position among European Union member states, with the lowest per capita healthcare expenditure (€990 annually) yet demonstrating the second-highest growth rate in health spending between 2014 and 2022. This economic paradox reflects the dynamics of a developing market operating under resource constraints while facing growing needs from an aging population. The medical devices sector is an essential component of Bulgaria‘s healthcare system, including products ranging from simple consumables to sophisticated implantable devices and advanced diagnostic equipment. This review examines the Bulgarian medical device landscape through multiple dimensions: historical evolution from medieval surgical instruments to contemporary AI-integrated systems, fundamental distinctions from pharmaceuticals and dietary supplements based on mechanisms of action, the comprehensive regulatory framework under Medical Device Regilation (MDR) 2017/745, institutional interactions among key organizations (the Bulgarian Drug Agency, the National Health Insurance Fund, the Ministry of Health), and market trends shaped by demographic transformation. With a population of 6.44 million (23.8% over 65 years), Bulgaria faces pressing demographic challenges that reshape healthcare demand patterns. The analysis reveals a market exceeding €300 million, dependent on imports (>90%), with limited domestic manufacturing capacity. Despite the financial constraints, Bulgaria has achieved an international recognition through top-tier regulatory inspections and active participation in the European regulatory structures. The review outlines perspectives for short-term priorities (2025–2027), medium-term objectives (2027–2030), and long-term vision (2030+) for sector development, emphasizing the digital transformation, regional coverage improvement, and demographic crisis management through the technological innovation.
- 27 April 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessMedical devices in Bulgaria: Regulatory framework, market dynamics, and institutional development
Bulgaria occupies a unique position among European Union member states, with the lowest per capita healthcare expenditure (€990 annually) yet demonstrating the second-highest growth rate in health spending between 2014 and 2022. This economic paradox reflects the dynamics of a developing market operating under resource constraints while facing growing needs from an aging population. The medical devices sector is an essential component of Bulgaria‘s healthcare system, including products ranging from simple consumables to sophisticated implantable devices and advanced diagnostic equipment. This review examines the Bulgarian medical device landscape through multiple dimensions: historical evolution from medieval surgical instruments to contemporary AI-integrated systems, fundamental distinctions from pharmaceuticals and dietary supplements based on mechanisms of action, the comprehensive regulatory framework under Medical Device Regilation (MDR) 2017/745, institutional interactions among key organizations (the Bulgarian Drug Agency, the National Health Insurance Fund, the Ministry of Health), and market trends shaped by demographic transformation. With a population of 6.44 million (23.8% over 65 years), Bulgaria faces pressing demographic challenges that reshape healthcare demand patterns. The analysis reveals a market exceeding €300 million, dependent on imports (>90%), with limited domestic manufacturing capacity. Despite the financial constraints, Bulgaria has achieved an international recognition through top-tier regulatory inspections and active participation in the European regulatory structures. The review outlines perspectives for short-term priorities (2025–2027), medium-term objectives (2027–2030), and long-term vision (2030+) for sector development, emphasizing the digital transformation, regional coverage improvement, and demographic crisis management through the technological innovation.
- Open Access
- 19 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
The historical evolution of European medical device regulation: from fragmented national systems to a harmonized supranational framework
This review traces European medical device regulation from fragmented national systems to the harmonized framework established by Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR). It examines the pre-harmonization period (1957–1985), characterized by diverse national approaches in Western and Eastern Europe, including Bulgaria’s regulatory development during the post-communist transition. It explores the New Approach to technical harmonization (1985), the directive era (1990–2000), and how regulatory crises—including the Guidant pacemaker failures, the DePuy ASR hip prosthesis scandal, and the PIP breast implant fraud—served as stress tests confirming the necessity of reforms. Special attention is given to emerging challenges from artificial intelligence in medical devices following the adoption of the AI Act (Regulation (EU) 2024/1689).
- 19 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Open AccessThe historical evolution of European medical device regulation: from fragmented national systems to a harmonized supranational framework
This review traces European medical device regulation from fragmented national systems to the harmonized framework established by Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR). It examines the pre-harmonization period (1957–1985), characterized by diverse national approaches in Western and Eastern Europe, including Bulgaria’s regulatory development during the post-communist transition. It explores the New Approach to technical harmonization (1985), the directive era (1990–2000), and how regulatory crises—including the Guidant pacemaker failures, the DePuy ASR hip prosthesis scandal, and the PIP breast implant fraud—served as stress tests confirming the necessity of reforms. Special attention is given to emerging challenges from artificial intelligence in medical devices following the adoption of the AI Act (Regulation (EU) 2024/1689).
- Open Access
- 13 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-28
Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review
Selective sodium-glucose cotransporter-2 (SGLT2) inhibitors act only at the renal level, promoting glucose excretion. Their glucose-independent mechanism makes them effective in advanced type 2 diabetes mellitus, when pancreatic β-cell reserves are permanently reduced. In addition to glucosuria, SGLT2 inhibition induces natriuresis, contributing to negative salt and water balance. The aim of this study is to evaluate the efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus through a systematic review of scientific publications, examining clinical trials with this class of glucose-lowering medicinal products. We performed a literature search in MEDLINE, the Central Library of Medicine, and peer-reviewed journals for the period January 2004 to December 2024. The systematic review is conducted in accordance with the PRISMA standard and the PICOS tool. The results of the PICOS analysis show that the most significant reduction in HbA1c level is observed after administration of Ertugliflozin 15 mg (−0.90%) and Ipragliflozin 50 mg (−0.88%). The body weight reduction is the most significant after administration of Ertugliflozin 15 mg, by 2.93 kg. Common adverse drug reactions include urinary tract infections and genital mycotic infections. The results of the conducted PICOS analysis prove the high efficacy of SGLT2 inhibitors in terms of their cardiovascular safety and cardio-renal benefits. In addition to their glucose-lowering properties, they are associated with a very low risk of hypoglycemia.
- 13 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-28
Open AccessEfficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review
Selective sodium-glucose cotransporter-2 (SGLT2) inhibitors act only at the renal level, promoting glucose excretion. Their glucose-independent mechanism makes them effective in advanced type 2 diabetes mellitus, when pancreatic β-cell reserves are permanently reduced. In addition to glucosuria, SGLT2 inhibition induces natriuresis, contributing to negative salt and water balance. The aim of this study is to evaluate the efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus through a systematic review of scientific publications, examining clinical trials with this class of glucose-lowering medicinal products. We performed a literature search in MEDLINE, the Central Library of Medicine, and peer-reviewed journals for the period January 2004 to December 2024. The systematic review is conducted in accordance with the PRISMA standard and the PICOS tool. The results of the PICOS analysis show that the most significant reduction in HbA1c level is observed after administration of Ertugliflozin 15 mg (−0.90%) and Ipragliflozin 50 mg (−0.88%). The body weight reduction is the most significant after administration of Ertugliflozin 15 mg, by 2.93 kg. Common adverse drug reactions include urinary tract infections and genital mycotic infections. The results of the conducted PICOS analysis prove the high efficacy of SGLT2 inhibitors in terms of their cardiovascular safety and cardio-renal benefits. In addition to their glucose-lowering properties, they are associated with a very low risk of hypoglycemia.
- Open Access
- 2 August 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-17
Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists. We performed a literature search of scientific publications in MEDLINE and Central Library of Medicine databases by predefined keywords for the period 2004 to 2023 containing information for the efficacy and safety of GLP-1 receptor agonists. The systematic review is in accordance with the PRISMA standard and the PICOS tool. There is strong evidence to support the use of GLP-1 agonists in overweight or obese patients who have cardiovascular disease, impaired renal function or are at high risk of hypoglycaemia. The safety profiles of all representatives of this class are similar. Semaglutide and Tirzepatide demonstrated the highest efficacy in reducing glycated hemoglobin (HbA1c) - 1.70% and 2.37%, respectively. We found the superiority of GLP-1 receptor agonists over other antidiabetic medicinal prodycts in terms of HbA1c reduction and weight loss without the risk of hypoglycemic episodes.
- 2 August 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-17
Open AccessSystematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists. We performed a literature search of scientific publications in MEDLINE and Central Library of Medicine databases by predefined keywords for the period 2004 to 2023 containing information for the efficacy and safety of GLP-1 receptor agonists. The systematic review is in accordance with the PRISMA standard and the PICOS tool. There is strong evidence to support the use of GLP-1 agonists in overweight or obese patients who have cardiovascular disease, impaired renal function or are at high risk of hypoglycaemia. The safety profiles of all representatives of this class are similar. Semaglutide and Tirzepatide demonstrated the highest efficacy in reducing glycated hemoglobin (HbA1c) - 1.70% and 2.37%, respectively. We found the superiority of GLP-1 receptor agonists over other antidiabetic medicinal prodycts in terms of HbA1c reduction and weight loss without the risk of hypoglycemic episodes.
- Open Access
- 26 June 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-19
Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria
Summary: Chronic myelogenous leukemia (CML) is a pluripotent hemopoietic stem cell malignancy characterized by the presence of a BCR-ABL1 fusion gene derived from a balanced translocation between the long arms of chromosomes 9 and 22 [t(9;22) (q34; q11)] known as the Philadelphia (Ph) chromosome. CML is an acquired hematopoietic stem cell disease common to myelo- and lymphopoiesis, characterized by uncontrolled proliferation of granulopoiesis (Shuvaev et al. 2015; Yordanov and Varbanova 2019). Relevance and goals: Second-generation tyrosine kinase inhibitors (TKIs) (nilotinib, dasatinib, and bosutinib) have an advantage over imatinib (first-generation) in the frequency and speed of achieving cytogenetic and molecular responses in the treatment of chronic myelogenous leukemia (CML), but they cause severe adverse effects and are much more expensive than imatinib, especially if we compare them to the prices of the registered generic products of Imatinib and Dasatinib. “Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia”, reported on 10/20/2021 by Pierre Perrin-Montlouis. In the first direct comparison of these two oral therapies back in 2009 (Тasigna (nilotinib) 2009), as first-line treatment for CML, the results of Tasigna showed statistically significant improvement over Glivec in every measure of efficacy, including major molecular response (MMR), complete cytogenetic response (CCyR) and prevention of progression to accelerated or blast phase, with responses achieved faster in the Tasigna group than in the Glivec group. Furthermore, in the last ten years, CML patients who have achieved a stable deep molecular response for at least 2 years have been included in clinical trials for the management of treatment-free remission (TFR) (Kim et al. 2013; Saußele et al. 2016). On the other hand, the ever-increasing costs of diagnosis, treatment and monitoring of the response of CML to the various therapeutic strategies require conducting pharmacoeconomic analyses of the cost-effectiveness and cost-utility types in order to evaluate which are the cost-effective strategies with a view to introducing them into therapeutic practice. The present study aims to analyze the pharmacoeconomic efficiency of the TKI inhibitors used by the patients with CML-CP in the first and second lines, treated in the hematology clinic at UMHAT “St. George”, MU- Plovdiv during the period 2018–2022. Methods: An economic analysis of the medicinal use of TKIs for a 5-year period (2018–2022) was performed at the national level according to data from the National Health Insurance Fund and the availability, accessibility, and usability of original and generic TKIs in Bulgaria were evaluated. The direct medical costs for the therapy of all patients were calculated, including the costs of the TKI therapy, laboratory tests, and monitoring of the molecular response for the entire treatment period from the appointment of the TKI therapy until the end of 2022. A comparative analysis was conducted to assess the cost-effectiveness of the different therapeutic strategies with TKIs on the first and second lines of treatment of patients with CML-CP in the hematology clinic at UMHAT “St. George” Medical University, Plovdiv, using the decision analysis method and conducting one-way and probalistic sensitivity analyses. Results: The sensitivity analyzes of all pharmacoeconomic models showed the robustness and reliability of the obtained results. The threshold limits of medical costs and the frequency of achieving a deep molecular response determining the choice of first- and second-generation tyrosine kinase inhibitors as first- and second-line therapy for patients with chronic myeloid leukemia in the chronic phase have been determined. Prescribing doctors prefer the original MPs to generic analogues, which is also assumed by the current regulations, according to which even for expensive MPs dispensing by protocols, the prescription is by trade and not by international non-proprietary names (INN), which is why the use of the much cheaper generic MPs is negligibly low compared to original MPs. A personalized approach to the patient’s therapy and monitoring the patient’s molecular response to it, as well as stopping therapy in 25–30% of patients suitable to stop it safely when in TFR phase with a probability of more than 50% of not having a relapse will save additional costs that, by improving the cost-effectiveness of therapy for patients with CML, will be directed towards the treatment of new patients with this or other diseases. Conclusion: These pharmacoeconomic models can be applied to improve diagnostic and therapeutic standards in clinical practice and for the efficient use of the very limited resources for health care in countries like Bulgaria. The conducted cost-effectiveness analyses confirmed that the hematologists at the University Center in Plovdiv adhere to the recommendations of Leukemia Net and the Bulgarian Medical Society of Hematology and achieve not only good therapeutic but also pharmacoeconomic efficiency in the treatment of CML-СР patients in first- and second- line therapy.
- 26 June 2024
- Published by Pensoft Publishers in Pharmacia
- Vol. 71, 1-19
Open AccessAnalysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria
Summary: Chronic myelogenous leukemia (CML) is a pluripotent hemopoietic stem cell malignancy characterized by the presence of a BCR-ABL1 fusion gene derived from a balanced translocation between the long arms of chromosomes 9 and 22 [t(9;22) (q34; q11)] known as the Philadelphia (Ph) chromosome. CML is an acquired hematopoietic stem cell disease common to myelo- and lymphopoiesis, characterized by uncontrolled proliferation of granulopoiesis (Shuvaev et al. 2015; Yordanov and Varbanova 2019). Relevance and goals: Second-generation tyrosine kinase inhibitors (TKIs) (nilotinib, dasatinib, and bosutinib) have an advantage over imatinib (first-generation) in the frequency and speed of achieving cytogenetic and molecular responses in the treatment of chronic myelogenous leukemia (CML), but they cause severe adverse effects and are much more expensive than imatinib, especially if we compare them to the prices of the registered generic products of Imatinib and Dasatinib. “Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia”, reported on 10/20/2021 by Pierre Perrin-Montlouis. In the first direct comparison of these two oral therapies back in 2009 (Тasigna (nilotinib) 2009), as first-line treatment for CML, the results of Tasigna showed statistically significant improvement over Glivec in every measure of efficacy, including major molecular response (MMR), complete cytogenetic response (CCyR) and prevention of progression to accelerated or blast phase, with responses achieved faster in the Tasigna group than in the Glivec group. Furthermore, in the last ten years, CML patients who have achieved a stable deep molecular response for at least 2 years have been included in clinical trials for the management of treatment-free remission (TFR) (Kim et al. 2013; Saußele et al. 2016). On the other hand, the ever-increasing costs of diagnosis, treatment and monitoring of the response of CML to the various therapeutic strategies require conducting pharmacoeconomic analyses of the cost-effectiveness and cost-utility types in order to evaluate which are the cost-effective strategies with a view to introducing them into therapeutic practice. The present study aims to analyze the pharmacoeconomic efficiency of the TKI inhibitors used by the patients with CML-CP in the first and second lines, treated in the hematology clinic at UMHAT “St. George”, MU- Plovdiv during the period 2018–2022. Methods: An economic analysis of the medicinal use of TKIs for a 5-year period (2018–2022) was performed at the national level according to data from the National Health Insurance Fund and the availability, accessibility, and usability of original and generic TKIs in Bulgaria were evaluated. The direct medical costs for the therapy of all patients were calculated, including the costs of the TKI therapy, laboratory tests, and monitoring of the molecular response for the entire treatment period from the appointment of the TKI therapy until the end of 2022. A comparative analysis was conducted to assess the cost-effectiveness of the different therapeutic strategies with TKIs on the first and second lines of treatment of patients with CML-CP in the hematology clinic at UMHAT “St. George” Medical University, Plovdiv, using the decision analysis method and conducting one-way and probalistic sensitivity analyses. Results: The sensitivity analyzes of all pharmacoeconomic models showed the robustness and reliability of the obtained results. The threshold limits of medical costs and the frequency of achieving a deep molecular response determining the choice of first- and second-generation tyrosine kinase inhibitors as first- and second-line therapy for patients with chronic myeloid leukemia in the chronic phase have been determined. Prescribing doctors prefer the original MPs to generic analogues, which is also assumed by the current regulations, according to which even for expensive MPs dispensing by protocols, the prescription is by trade and not by international non-proprietary names (INN), which is why the use of the much cheaper generic MPs is negligibly low compared to original MPs. A personalized approach to the patient’s therapy and monitoring the patient’s molecular response to it, as well as stopping therapy in 25–30% of patients suitable to stop it safely when in TFR phase with a probability of more than 50% of not having a relapse will save additional costs that, by improving the cost-effectiveness of therapy for patients with CML, will be directed towards the treatment of new patients with this or other diseases. Conclusion: These pharmacoeconomic models can be applied to improve diagnostic and therapeutic standards in clinical practice and for the efficient use of the very limited resources for health care in countries like Bulgaria. The conducted cost-effectiveness analyses confirmed that the hematologists at the University Center in Plovdiv adhere to the recommendations of Leukemia Net and the Bulgarian Medical Society of Hematology and achieve not only good therapeutic but also pharmacoeconomic efficiency in the treatment of CML-СР patients in first- and second- line therapy.
- Open Access
- 21 November 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (4) , 1355-1362
Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria
Aim. The aim of this study is to evaluate treatment retrospectively, response to the therapy and outcomes in patients with chronic myeloid leukemia (CML) and to what extent the European recommendations of LeukemiaNET (ELN) are followed at the Hematology Clinic, University Hospital “St. Georgi”, MU Plovdiv. Methods. All patients with Ph+, BCR-ABL1+ CML who were treated and observed between 01.01.2018 and 12.31.2022 at the clinic were included in the study and were analyzed retrospectively. Results. One hundred and eighty-eight patients with a mean age of 61.26 (21–91) years were analyzed. 151 (80.3%) were in chronic phase (CP), 27 (14.4%) in accelerating one and 10 (5.3%) in blast crisis. The actual overall survival rate was 79.26%, while for CP it is very high – 86.75%, and the mortality rate is 20.74%. All patients received some form of tyrosine kinase inhibitors therapy (TKIs-therapy). The first line TKI was imatinib in 120 patients (64%), and 68 (36%) received a second-generation TKI. Treatment response was monitored with TKIs by RT-qPCR. Conclusion. CML patients treated in the hematology clinic receive standard care in accordance with ELN and BMSH recommendations. Overall survival (OS) in routine care is comparable to published data from international studies. Molecular monitoring provides a good basis for disease control in CP. There are unmet needs in the treatment of patients in advanced stages.
- 21 November 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (4) , 1355-1362
Open AccessAnalysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria
Aim. The aim of this study is to evaluate treatment retrospectively, response to the therapy and outcomes in patients with chronic myeloid leukemia (CML) and to what extent the European recommendations of LeukemiaNET (ELN) are followed at the Hematology Clinic, University Hospital “St. Georgi”, MU Plovdiv. Methods. All patients with Ph+, BCR-ABL1+ CML who were treated and observed between 01.01.2018 and 12.31.2022 at the clinic were included in the study and were analyzed retrospectively. Results. One hundred and eighty-eight patients with a mean age of 61.26 (21–91) years were analyzed. 151 (80.3%) were in chronic phase (CP), 27 (14.4%) in accelerating one and 10 (5.3%) in blast crisis. The actual overall survival rate was 79.26%, while for CP it is very high – 86.75%, and the mortality rate is 20.74%. All patients received some form of tyrosine kinase inhibitors therapy (TKIs-therapy). The first line TKI was imatinib in 120 patients (64%), and 68 (36%) received a second-generation TKI. Treatment response was monitored with TKIs by RT-qPCR. Conclusion. CML patients treated in the hematology clinic receive standard care in accordance with ELN and BMSH recommendations. Overall survival (OS) in routine care is comparable to published data from international studies. Molecular monitoring provides a good basis for disease control in CP. There are unmet needs in the treatment of patients in advanced stages.
- Open Access
- 18 August 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (3) , 643-648
Level of hypertension treatment adherence during pandemic
Adherence to antihypertensive medications is the cornerstone for achieving metabolic syndrome control. The aim of this study was to explore how the pandemic has affected the adherence of patients with high BP to prescribed antihypertensive drugs. This multicentre observational study utilized self-completed questionnaires among patients between June and November 2020. Overall, 842 patients were included in the study. The likelihood of adherence was assessed using the 5‐item version of the Medication Adherence Report Scale (MARS-5Professor Rob Horne). The average MARS score of the sample was 16.81, the median was 4.162, and the most common value was 3 (24.5% of respondents) for the patients treated during the pandemic. The study suggests that several sociodemographic factors but not the COVID pandemic play a role in treatment adherence.
- 18 August 2023
- Published by Pensoft Publishers in Pharmacia
- Vol. 70 (3) , 643-648
Open AccessLevel of hypertension treatment adherence during pandemic
Adherence to antihypertensive medications is the cornerstone for achieving metabolic syndrome control. The aim of this study was to explore how the pandemic has affected the adherence of patients with high BP to prescribed antihypertensive drugs. This multicentre observational study utilized self-completed questionnaires among patients between June and November 2020. Overall, 842 patients were included in the study. The likelihood of adherence was assessed using the 5‐item version of the Medication Adherence Report Scale (MARS-5Professor Rob Horne). The average MARS score of the sample was 16.81, the median was 4.162, and the most common value was 3 (24.5% of respondents) for the patients treated during the pandemic. The study suggests that several sociodemographic factors but not the COVID pandemic play a role in treatment adherence.
- Open Access
- 9 March 2018
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 24 (1) , 1928-1931
SCREENING AND RISK ASSESSMENT FOR DEPRESSION IN COMMUNITY PHARMACY- PILOT STUDY
- 9 March 2018
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 24 (1) , 1928-1931
Open AccessSCREENING AND RISK ASSESSMENT FOR DEPRESSION IN COMMUNITY PHARMACY- PILOT STUDY